Cancer

Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

4 months ago

Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement

Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for…

4 months ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON,…

4 months ago

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

4 months ago

CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks

Bernard Coulie and Kevin Marks bring significant corporate, drug development, and compliance experience to the CMTA BoardThe CMTA Board and…

4 months ago

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs,…

4 months ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

4 months ago

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticlesTargeting safer…

4 months ago

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.…

4 months ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows…

4 months ago